6 recruiting, 3 completed, 1 not yet recruiting. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 6, Completed 3, Not yet recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Alcohol Use Disorder (AUD): new trials by email Literature Review of Alcohol Use Disorder (AUD) trials Research Report on Alcohol Use Disorder (AUD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg - Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30) | Phase 1 | Recruiting | Yale University | 90 | 2026-10-01 | 2026-11-04 |
| Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) Tirzepatide, Placebo, [11C]raclopride plus drug - Alcohol Use Disorder (AUD) | Phase 1 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 176 | 2026-05-20 | 2026-10-13 |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) Ketamine, Cognitive Behavioural Therapy - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | South West Sydney Local Health District | 20 | 2025-12-10 | 2025-11-25 |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Recruiting | Yale University | 63 | 2025-08-04 | 2026-09-10 |
| Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg - Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 1 | Recruiting | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 10 | 2025-07-28 | 2026-09-21 |
| Diclofenac Dose Response Study Diclofenac 100mg, Diclofenac 75mg, Diclofenac 50mg - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Completed | University of Maryland, Baltimore | 23 | 2024-12-01 | 2026-09-08 |
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant - Healthy Volunteers, Alcohol Use Disorder (AUD) | Phase 1 / Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 180 | 2024-11-21 | 2026-10-19 |
| Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers Mavoglurant - Alcohol Consumption, Heavy Drinker | Phase 1 | Recruiting | Yale University | 63 | 2024-07-01 | 2026-08-21 |
| Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg - Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 1 | Completed | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 10 | 2021-11-09 | 2023-10-26 |
| Study of DCR-AUD in Healthy Volunteers DCR-AUD, Placebo for DCR-AUD - Alcohol Use Disorder (AUD) | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 36 | 2021-09-21 | 2024-12-27 |
Alcoholism (10) · Alcohol Drinking (5) · Alcohol-Related Disorders (2) · Stress Disorders, Post-Traumatic (2) · Alcoholic Intoxication (1) · Chemically-Induced Disorders (1) · Depressive Disorder, Major (1) · Drinking Behavior (1) · Obesity (1) · Substance-Related Disorders (1)
Mental Disorders (10) · Chemically-Induced Disorders (9) · Substance-Related Disorders (9) · Alcohol-Related Disorders (8) · Behavior (6) · Drinking Behavior (5) · Stress Disorders, Traumatic (2) · Trauma and Stressor Related Disorders (2) · Body Weight (1) · Depressive Disorder (1) · Mood Disorders (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Overweight (1)
Dexmedetomidine (2) · Organization and Administration (2) · Cognitive Behavioral Therapy (1) · Diclofenac (1) · Diphenhydramine (1) · Ethanol (1) · Ketamine (1) · N,N-Dimethyltryptamine (1) · Pharmaceutical Preparations (1) · Psychotherapy (1) · Saline Solution (1) · Tirzepatide (1) · mavoglurant (1) · semaglutide (1) · suvorexant (1)
Yale University (3) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2) · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (2) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · South West Sydney Local Health District (1) · University of Maryland, Baltimore (1)
United States (9) · Australia (1)
Ismene Petrakis, MD (2) · Nora D Volkow Adler, M.D. (2) · Anahita Bassir Nia, MD (1) · Rajita Sinha (1) · Suchitra Krishnan, PhD (1)
P50AA012870 (1), R01AA032779 (1), R21AA030649 (1), U44AA027404 (1)